These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23453477)

  • 21. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
    Genovese MC; Kinnman N; de La Bourdonnaye G; Pena Rossi C; Tak PP
    Arthritis Rheum; 2011 Jul; 63(7):1793-803. PubMed ID: 21452293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effectiveness and safety of the treatment with tumour necrosis factor alpha antagonists in rheumatoid arthritis patients].
    Arenere Mendoza M; Navarro Aznárez H; Rabanaque Hernández MJ; Manero Ruiz FJ
    Med Clin (Barc); 2005 Jun; 125(1):35-6. PubMed ID: 15960943
    [No Abstract]   [Full Text] [Related]  

  • 26. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of ultrasonographic assessment of disease activity in response to tumor necrosis factor-α inhibitor treatment in rheumatoid arthritis: a prospective cohort study.
    Inanc N; Ozen G; Direskeneli H
    Clin Exp Rheumatol; 2016; 34(1):156. PubMed ID: 26575409
    [No Abstract]   [Full Text] [Related]  

  • 28. Swollen joint count as a predictor of response to anti-tumor necrosis factor alpha therapy in rheumatoid arthritis: comment on the article by Sokka and Pincus.
    Estrach C; Mpofu S; Thompson RN; Williams E; Abernethy VE; Moots RJ
    Arthritis Rheum; 2003 Dec; 48(12):3611-3; author reply 3613-5. PubMed ID: 14674016
    [No Abstract]   [Full Text] [Related]  

  • 29. Seropositive erosive rheumatoid arthritis (RA).
    Matthews C; Fitzgerald O
    Rheumatology (Oxford); 2006 Sep; 45(9):1100. PubMed ID: 16943373
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
    Payet S; Pereira B; Soubrier M; Mathieu S
    Semin Arthritis Rheum; 2012 Feb; 41(4):e4-5; author reply e6. PubMed ID: 22154222
    [No Abstract]   [Full Text] [Related]  

  • 31. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine?
    Simsek I
    Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects].
    Cavazzana I; Bobbio-Pallavicini F; Bazzani C; Bravi E; Zingarelli S; Ceribelli A; Caporali R; Cattaneo R; Franceschini F; Montecucco C
    Reumatismo; 2006; 58(4):275-82. PubMed ID: 17216016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
    Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry).
    Glace B; Gottenberg JE; Mariette X; Philippe R; Pereira B; Lequerré T; Berthelot JM; Dougados M; Toussirot E; Pham T; Allanore Y; Loeuille D; Euller-Ziegler L; Soubrier M
    Ann Rheum Dis; 2012 Aug; 71(8):1429-31. PubMed ID: 22504557
    [No Abstract]   [Full Text] [Related]  

  • 40. [Is the response to anti-TNFalpha treatment influenced by the presence of IgM rheumatoid factor, in Rheumatoid Arthritis patients?].
    Mourão AF; Santos FP; Falcão S; Barros R; Pinto TL; Mendes A; Castelão W; Nero P; Fonseca JE; Matos AA; Branco JC
    Acta Reumatol Port; 2008; 33(4):430-4. PubMed ID: 19078861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.